-+ 0.00%
-+ 0.00%
-+ 0.00%

Innovent's Zybrivo Wins CHMP Backing for First-Line Lung Cancer Treatment

PUBT·11/16/2026 00:02:03
Diffusion vocale
Innovent's Zybrivo Wins CHMP Backing for First-Line Lung Cancer Treatment
  • Innovent Biologics received a positive CHMP opinion recommending Zybrivo with chemotherapy for first-line treatment of advanced non-squamous non-small cell lung cancer.
  • A European Commission decision on marketing authorization is expected in the coming months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611151900PR_NEWS_USPR_____CN97975) on November 16, 2026, and is solely responsible for the information contained therein.